HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Agnes Y Y Lee Selected Research

Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)

5/2024Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
2/2024Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low Molecular Weight Heparin - The OSCAR-UK Study.
4/2023Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
1/2023Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
1/2021American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
10/2020Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
8/2020Anticoagulation practice patterns in COVID-19: A global survey.
9/2019Direct Oral Anticoagulants in Cancer Patients.
5/2019Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
10/2018Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Agnes Y Y Lee Research Topics

Disease

62Neoplasms (Cancer)
05/2024 - 06/2003
41Hemorrhage
05/2024 - 05/2002
39Venous Thromboembolism
05/2024 - 05/2002
27Thrombosis (Thrombus)
04/2023 - 05/2002
11Venous Thrombosis (Deep-Vein Thrombosis)
11/2023 - 05/2003
8COVID-19
07/2022 - 08/2020
7Pulmonary Embolism
12/2019 - 07/2003
5Thrombocytopenia (Thrombopenia)
05/2022 - 07/2015
4Inflammation (Inflammations)
07/2022 - 01/2004
3Critical Illness (Critically Ill)
07/2022 - 10/2020
3Atrial Fibrillation
09/2021 - 11/2019
2Leukemia
07/2023 - 10/2018
2Embolism (Embolus)
01/2020 - 11/2019
2Thromboembolism
11/2019 - 07/2003
1Intracranial Hemorrhages (Intracranial Hemorrhage)
11/2023
1Lymphoma (Lymphomas)
10/2022
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
05/2022
1Brain Neoplasms (Brain Tumor)
10/2020
1Urogenital Neoplasms
10/2020
1Cytokine Release Syndrome
01/2020
1Transient Ischemic Attack
11/2019
1Ischemic Stroke
11/2019
1Chronic Disease (Chronic Diseases)
01/2018
1Fatigue
01/2018
1Polyarteritis Nodosa (Periarteritis Nodosa)
08/2014
1Urticaria (Hives)
08/2014
1Neoplasm Metastasis (Metastasis)
05/2014
1Pain (Aches)
01/2012
1Postphlebitic Syndrome
03/2006
1Hypoxia (Hypoxemia)
01/2004
1Thrombophilia
01/2004
1Body Weight (Weight, Body)
07/2003

Drug/Important Bio-Agent (IBA)

43AnticoagulantsIBA
02/2024 - 05/2002
29Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
05/2024 - 06/2003
13RivaroxabanIBA
05/2024 - 01/2018
9Warfarin (Coumadin)FDA LinkGeneric
10/2022 - 09/2003
9Heparin (Liquaemin)FDA LinkGeneric
05/2022 - 12/2003
9fibrin fragment D (D-dimer)IBA
05/2022 - 05/2003
9Vitamin KFDA Link
09/2019 - 02/2005
7apixabanIBA
07/2023 - 01/2019
5Tinzaparin (Innohep)FDA Link
01/2018 - 06/2013
4Antineoplastic Agents (Antineoplastics)IBA
01/2010 - 06/2003
3edoxabanIBA
10/2022 - 05/2020
3Thromboplastin (Tissue Factor)IBA
01/2022 - 01/2004
3Biomarkers (Surrogate Marker)IBA
01/2020 - 06/2013
3Dalteparin (Dalteparin Sodium)FDA Link
05/2019 - 07/2003
3coumarinIBA
05/2019 - 07/2003
2VaccinesIBA
05/2022 - 01/2022
2AntibodiesIBA
05/2022 - 10/2020
2DabigatranFDA Link
11/2019 - 07/2015
2CreatinineIBA
11/2019 - 07/2015
2CoumarinsIBA
04/2005 - 07/2003
1Factor Xa InhibitorsIBA
04/2023
1Interleukin-6 InhibitorsIBA
07/2022
1tocilizumab (atlizumab)FDA Link
07/2022
1Dexamethasone (Maxidex)FDA LinkGeneric
07/2022
1COVID-19 VaccinesIBA
05/2022
1ChAdOx1 nCoV-19IBA
05/2022
1Serotonin (5 Hydroxytryptamine)IBA
05/2022
1Ad26COVS1IBA
05/2022
1Proteins (Proteins, Gene)FDA Link
01/2022
1CytokinesIBA
01/2021
1Fondaparinux (Arixtra)FDA Link
01/2021
1Blood Group Antigens (Blood Groups)IBA
10/2020
1ABO Blood-Group SystemIBA
10/2020
1Factor Xa (Coagulation Factor Xa)IBA
05/2020
1Chimeric Antigen ReceptorsIBA
01/2020
1vinyltriethoxysilane (VTES)IBA
05/2016
1Gastrointestinal AgentsIBA
12/2014
1Fibrinolytic Agents (Antithrombotic Agents)IBA
04/2012
1E-SelectinIBA
01/2004
1P-SelectinIBA
01/2004
1P-selectin ligand proteinIBA
01/2004
1LatexIBA
05/2003

Therapy/Procedure

33Therapeutics
10/2022 - 05/2002
6Drug Therapy (Chemotherapy)
01/2021 - 03/2006
4Central Venous Catheters
10/2018 - 03/2006
3Catheters
10/2018 - 03/2006
2Artificial Respiration (Mechanical Ventilation)
10/2021 - 10/2020
2Secondary Prevention
01/2018 - 12/2003
2Contraindications
08/2015 - 04/2014
1Anesthesia
09/2023
1Immunomodulation
05/2022
1Operative Surgical Procedures
01/2021
1Cardiopulmonary Resuscitation (CPR)
12/2019
1Platelet Transfusion (Blood Platelet Transfusions)
10/2018
1Vena Cava Filters (Inferior Vena Cava Filter)
10/2009
1Duration of Therapy
10/2009
1Subcutaneous Injections
12/2003